Nestron's male contraceptive gel, NesT, has shown success in reducing sperm counts, with 86% of men achieving effective levels by week 15.

Researchers at Baylor College of Medicine have discovered a potential non-hormonal male contraceptive targeting the protein STK33, which has shown 100% effectiveness in reducing fertility in male mice.

Utilizing DNA-Encoded Libraries (DELs), scientists identified potent inhibitors like CDD-2807 that bind to STK33, offering a promising pathway for the development of a reversible male birth control method.

The compound temporarily blocks STK33 in mice, leading to abnormal sperm production and infertility, with no other adverse effects observed.

Promega Corporation played a crucial role in the research, showcasing the safety and specificity of the contraceptive molecule in male mice.

A new hormonal gel containing testosterone and Nestorone has shown promising results in a phase 2 trial, with 86% of men reaching sperm suppression in just eight weeks.

This gel acts faster than previous methods and requires less testosterone, and is effective in reducing sperm count to prevent pregnancy within 15 weeks.

Interest in male birth control is on the rise, with surveys indicating a willingness to try new methods, especially following recent legal developments.

A Senate bill is being voted on to protect access to contraceptives, and the next step for the gel is a larger phase 3 clinical trial.

Pharmaceutical companies may increase investment in male birth control options if a drug is approved by the FDA, as male birth control methods continue to evolve to meet the demand for effective contraception.